CL2020003101A1 - Sales de sepiapterina farmacéuticamente aceptables. - Google Patents

Sales de sepiapterina farmacéuticamente aceptables.

Info

Publication number
CL2020003101A1
CL2020003101A1 CL2020003101A CL2020003101A CL2020003101A1 CL 2020003101 A1 CL2020003101 A1 CL 2020003101A1 CL 2020003101 A CL2020003101 A CL 2020003101A CL 2020003101 A CL2020003101 A CL 2020003101A CL 2020003101 A1 CL2020003101 A1 CL 2020003101A1
Authority
CL
Chile
Prior art keywords
sepiapterin
salts
relates
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
CL2020003101A
Other languages
English (en)
Inventor
Daniel E Levy
Neil Smith
Jonathan Reis
Hiroshi Yoshino
Taichi Komoda
Yuichi Shiro
Shunichi Murata
Takayoshi Matsumoto
Kaito Kishimoto
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of CL2020003101A1 publication Critical patent/CL2020003101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a sales y/o co-cristales farmacéuticos nuevos de sepiapterina que exhiben propiedades mejoradas. En particular, la invención se refiere a sales de sepiapterina con estabilidad mejorada. La invención también se refiere a composiciones farmacéuticas que incluyen una cantidad farmacéuticamente eficaz de una o más sales y/o cocristales de sepiapterina, y también métodos de tratamiento de trastornos relacionados con tetrahidrobiopterina que incluyen la administración de una sal y/o co-cristal de sepiapterina de la invención a un sujeto que lo requiera.
CL2020003101A 2018-05-30 2020-11-27 Sales de sepiapterina farmacéuticamente aceptables. CL2020003101A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862678025P 2018-05-30 2018-05-30
US201862726612P 2018-09-04 2018-09-04
US201962822336P 2019-03-22 2019-03-22
GC201937661 2019-05-28

Publications (1)

Publication Number Publication Date
CL2020003101A1 true CL2020003101A1 (es) 2021-05-14

Family

ID=68699017

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003101A CL2020003101A1 (es) 2018-05-30 2020-11-27 Sales de sepiapterina farmacéuticamente aceptables.

Country Status (13)

Country Link
US (1) US20210269443A1 (es)
EP (1) EP3807279A4 (es)
JP (2) JP2021527031A (es)
KR (1) KR20210038848A (es)
CN (1) CN112543758A (es)
AU (1) AU2019277372A1 (es)
BR (1) BR112020024332A2 (es)
CA (1) CA3102070A1 (es)
CL (1) CL2020003101A1 (es)
CO (1) CO2020016582A2 (es)
IL (1) IL279101A (es)
MX (1) MX2020012978A (es)
WO (1) WO2019232120A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116903624A (zh) 2016-11-29 2023-10-20 Ptc医疗Mp公司 墨蝶呤及其盐的多晶型物
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN112703002A (zh) 2018-05-30 2021-04-23 Ptc医疗Mp公司 增加墨蝶呤血浆暴露的方法
US20210161901A1 (en) * 2018-05-30 2021-06-03 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
US20220273661A1 (en) 2019-08-05 2022-09-01 Ptc Therapeutics Mp, Inc. Use of sepiapterin and metabolites thereof to treat radiation exposure
MX2022003585A (es) 2019-09-25 2022-04-19 Ptc Therapeutics Mp Inc Metodos para tratar hiperfenilalaninemia.
WO2021150983A1 (en) 2020-01-24 2021-07-29 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
CN114621198A (zh) * 2020-12-11 2022-06-14 北京夏禾科技有限公司 有机电致发光材料及其器件
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
EP4291196A1 (en) 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753656A (en) * 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
EP2139485B1 (en) * 2007-04-11 2012-10-17 BioMarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
JP2012512848A (ja) * 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
JP5066756B2 (ja) * 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin
CN109640957A (zh) * 2016-06-13 2019-04-16 梅哈里医学院 一氧化氮合酶途径对口腔健康的调节
EP3548487A4 (en) * 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
CN116903624A (zh) * 2016-11-29 2023-10-20 Ptc医疗Mp公司 墨蝶呤及其盐的多晶型物
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.

Also Published As

Publication number Publication date
CA3102070A1 (en) 2019-12-05
MX2020012978A (es) 2021-04-28
JP2021527031A (ja) 2021-10-11
JP2024063143A (ja) 2024-05-10
CN112543758A (zh) 2021-03-23
AU2019277372A1 (en) 2021-01-21
IL279101A (en) 2021-01-31
KR20210038848A (ko) 2021-04-08
BR112020024332A2 (pt) 2021-02-23
EP3807279A1 (en) 2021-04-21
CO2020016582A2 (es) 2021-04-08
EP3807279A4 (en) 2022-04-06
US20210269443A1 (en) 2021-09-02
WO2019232120A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
CL2020003101A1 (es) Sales de sepiapterina farmacéuticamente aceptables.
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
DOP2016000156A (es) Composiciones farmacã¿uticas que comprenden azd9291.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CL2021001537A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
BR112017011623A2 (pt) composições farmacêuticas e processo para a preparação de uma composição
CO2021017343A2 (es) Formas de sales cristalinas de un inhibidor de cinasas